Skip to content
Quebec News Tribune – Lifestyle
Author:
Immutep Limited
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
March 19, 2026
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
March 13, 2026
←
Previous Page
1
2